Benno Lex
4 Papers
27 Citations
Benno Lex is an academic researcher. The author has contributed to research in topics: Internal medicine & Breast cancer. The author has an hindex of 2, co-authored 2 publications.
Chat about Author
Papers
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial
Jacobus Pfisterer,Catherine M Shannon,Klaus Baumann,Joern Rau,Philipp Harter,Florence Joly,Jalid Sehouli,Ulrich Canzler,Barbara Schmalfeldt,Barbara Schmalfeldt,Andrew Dean,Alexander Hein,Alain G. Zeimet,Lars Hanker,Thierry Petit,Frederik Marmé,Ahmed El-Balat,Rosalind Glasspool,Nikolaus de Gregorio,Sven Mahner,Sven Mahner,Tarek M Meniawy,Tjoung-Won Park-Simon,Marie-Ange Mouret-Reynier,Cristina Costan,Werner Meier,Alexander Reinthaller,Jeffrey C Goh,Tifenn Lharidon,Sally Baron Hay,Stefan Kommoss,Andreas du Bois,Jean-Emmanuel Kurtz,Sven Ackermann,Christoph Anthuber,Mustafa Aydogdu,Angelika Baldauf,Wolfgang Bauer,Dirk Behringer,Antje Belau,Alexandra Bender,C Brucker,Alexander Burges,Trygve Daabach,Dominik Denschlag,Mustafa Deryal,Steffen Dörfel,Juliane Ebert,Tanja Fehm,Susanne Maria Feidicker,Gabriele Feisel-Schwickardi,Ricardo Felberbaum,Matthias Frank,Gerhard Gebauer,Bernd Gerber,Axel Gerhardt,Andrea Grafe,Martin Griesshammer,Eva-Maria Grischke,Isolde Gröll,Martina Gropp-Meier,Dietrich Hager,Volker Hanf,Carla Verena Hannig,Peer Hantschmann,Tanja Hauzenberger,Uwe Herwig,Martin Heubner,Carsten Hielscher,Felix Hilpert,Thomas Hitschold,Manfred Hofmann,Christian Jackisch,Wolfgang Janni,Ludwig Kiesel,Yon-Dschun Ko,Hans-Joachim Koch,Petra Krabisch,Peter Krieger,Thomas Kubin,Thorsten Kühn,Björn Lampe,Peter Ledwon,Sabine Lemster,Benno Lex,Clemens Liebrich,Ralf Lorenz,Hans-Joachim Lück,Peter Mallmann,Wolfgang Meinerz,Götz Menke,Volker Möbus,Thomas G. Müller,Volker Müller,Tanja Neunhöffer,Angelika Ober,G. Oskay-Özcelik,Horst Ostertag,Martin Pölcher,Beate Rautenberg,Daniel Rein,Wilhelm Reiter,Andreas Rempen,Ingo B. Runnebaum,Marcus Schmidt,Sabine Schnohr,Heinz Scholz,Willibald Schröder,Eike Simon,Antje Sperfeld,Annette Steckkönig,Hans-Georg Strauß,Ronaldo Stuth,Jürgen Terhaag,Falk Thiel,Marc Thill,Oliver Tomé,Christoph Uleer,Susanne Vogel,Hermann Voß,Michael Weigel,Ulrich Winkler,Arthur Wischnik,Tobias Zeiser,Andreas Zorr,R.M. Glasspool,Emma Hudson,Rachel Jones,Judith Lafleur,Christian Marth,Edgar Petru,Yoland Antill,Mary Azer,Sally Baron-Hay,Philip Beale,Stephen Begbie,Allison Black,Karen Briscoe,Andrew Dean,Jeffrey C. Goh,Sandra Harvey,Chee Lee,Marco Matos,Tarek Meniawy,Inger Olesen,Catherine Shannon,Paul A. Vasey,Sophie Abadie-Lacourtoisie,Olivier Arsene,Sophie Barthier,Célia Becuwe-Roemer,Dominique Berton-Rigaud,Maria Cappiello-Bataller,Stéphanie Catala,Francesco Del Piano,Gael Deplanque,Raymond Despax,Nadine Dohollou,Claire Garnier-Tixidré,Julien Grenier,Emmanuel Guardiola,Anne-Claire Hardy-Bessard,Claudia Lefeuvre-Plesse,Marianne Leheurteur,Anne Lesoin,Charles-Briac Levache,Raffaele Longo,Alain Lortholary,Jérôme Meunier,Nadia Raban,Olivier Romano,Jean-Michel Vannetzel,Alain Zannetti +172 more
TL;DR: This multicentre, open-label, randomised, phase 3 trial was to compare a standard bevacizumab-containing regimen versus carboplatin-pegylated liposomal doxorubicin combined with bevacsumab for progression-free survival in recurrent ovarian cancer.
Breast cancer risk assessment in a mammography screening program and participation in the IBIS-II chemoprevention trial
Christian R. Loehberg,Sebastian M. Jud,Lothar Haeberle,Katharina Heusinger,Gerhard Dilbat,Alexander Hein,Claudia Rauh,Peter Dall,Nadine Rix,Sabrina Heinrich,Stefan Buchholz,Benno Lex,Barbara Reichler,Boris Adamietz,Ruediger Schulz-Wendtland,Matthias W. Beckmann,Peter A. Fasching +16 more
TL;DR: Offering chemoprevention to women within a mammography screening unit as part of a paper-based survey resulted in low participation rates for both, the survey and the final participation in the IBIS-II trial.
Current clinical practice and outcome of neoadjuvant chemotherapy for early breast cancer: analysis of individual data from 94,638 patients treated in 55 breast cancer centers
O. Ortmann,Jens-Uwe Blohmer,Nora Tabea Sibert,S. Brucker,Achim Wöckel,Anton Scharl,Souleymane Dieng,Julia Ferencz,Elisabeth C. Inwald,Simone Wesselmann,Christopher E. Kowalski,E. K. Denisjuk,Roland Csorba,Daniela Rezek,Susanne Peschel,Dominik Denschlag,Friedemann Schad,D. Dieterle,Benno Lex,Luisa Rieger,Felix Flock,A. Cramer,H. J. Strittmatter,J. Bettscheider,Cecilia Lindnér,Andrea Stefek,Wladimir Pauker,Arnd Hönig,Michael G. Schrauder,D.Seeger,Anke Kleine-Tebbe,A. Bleimehl,Ursula Groh,Gerhard Gebauer,H.-W. Vollert,A. Zorr,W. Friedmann,P Krabisch,S. Fritz,A. Schwämmle,W. Lucke,Sabine Schmatloch,W. Heyl,Petra Deuschle,Michael C. Arfsten,P. Scheler,A. Ruf-Dördelmann,Barbara Brückner,Laurie Bauer,Martin Koch,Jaume Monner,A. Nixdorf,A. Merte,Frank Beldermann,Wolfgang Janni,Riccardo Felberbaum,R.L. De Wilde,P. Bolkenius,Antje Lebrecht,Olaf Ortmann,E. F. Solomayer,Steffi Hartmann,Andreas D. Hartkopf +62 more
TL;DR: In this article , the authors analyzed data from 94,638 patients treated in 55 breast cancer centers to describe the current clinical practice of and outcomes after NACT under routine conditions.
CAPTOR-BC: Comprehensive analysis of spatial, temporal and molecular biomarkers predicting response and resistance to first-line treatment with ribociclib + ET in HR+, HER2- advanced breast cancer.
Peter A. Fasching,Sara Y. Brucker,H Huebner,Verena Thewes,Léa Volmer,Andreas D. Hartkopf,Hans-Christian Kolberg,Benno Lex,Bahriye Aktas,Nina Ditsch,Lothar Haeberle,Katharina Seitz,Daniel Anetsberger,Naiba Nabieva,C M Roos,Erik Belleville,Andreas Schneeweiss,Volkmar Mueller,Wolfgang Janni,Tanja Fehm +19 more
TL;DR: The CAPTOR-BC (NCT054552213) study as discussed by the authors is a single-arm, open-label phase IV study evaluating the combination of ribociclib and ET according to SmPC in the first-line treatment of HR+ HER2- advanced breast cancer to identify and validate molecular and non-molecular biomarkers predictive of drug response and resistance.
1